Vaccine strategy enters new era

  • April 29, 2014

BETHESDA, Md. — A population-based approach to vaccine development and administration is rapidly evolving into an individualized treatment strategy based on a range of biological processes that shape human immunity to viruses, according to Gregory A. Poland, MD, of the Mayo Clinic, who delivered his keynote lecture here at the 2014 Annual Conference on Vaccine Research.

The new approach, coined “predictive vaccinology,” takes into account numerous individual factors, including gender, race/ethnicity and genotype, which can be used to predict a patient’s response to vaccination and aid in the development of more effective vaccines, especially against highly variable viruses. As opposed to a “one-size-fits-all” vaccination strategy, this individualized approach can help experts determine a patient’s need for a particular vaccine, the dosage required to induce an immune response, and the likelihood of adverse events.

Disclosures: Poland is the chair of a committee overseeing investigational vaccine trials conducted by Merck, Novartis, PaXVax Inc. and Sanofi Pasteur. This research has been reviewed by the Mayo Clinic conflict of interest review board and was conducted in compliance with Mayo Clinic conflict of interest policies.